Cost per response analysis of deucravacitinib versus apremilast and first-line biologics among patients with moderate to severe plaque psoriasis in the United States by Sang Hee Park, Mark Lambton, Jordana Schmier, Sara Hovland, Keith Wittstock, Vardhaman Patel

Get full text

Evaluating prevalence and consequence of residual disease in individuals with psoriasis receiving apremilast treatment: results from a US patient survey by Tina Bhutani, Sayeli Jayade, Sanika Rege, Hannah Penton, Vardhaman Patel, Samaneh Kalirai, Daniel Wolin, Kimberly Boyle, Lauren Seigel

Get full text

Real-world clinical outcomes and rationale for initiating abatacept as a first-line biologic for patients with anticitrullinated protein antibody- and rheumatoid factor-positive rh... by Alexandrina Balanean, Cherrishe Brown-Bickerstaff, Andrew Klink, Vardhaman Patel, Hanke Zheng, Laetitia N’Dri, Keith Wittstock, Bruce Feinberg, Mark Chaballa, Vadim Khaychuk, Jill Kaufman, Prathamesh Pathak, Gordon Lam